The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Immunological Responses to Exogenous Insulin
Abstract
Regardless of purity and origin, therapeutic insulins continue to be immunogenic in humans. However, severe immunological complications occur rarely, and less severe events affect a small minority of patients. Insulin autoantibodies (IAAs) may be detectable in insulin-naive individuals who have a high likelihood of developing type 1 diabetes or in patients who have had viral disorders, have been treated with various drugs, or have autoimmune disorders or paraneoplastic syndromes. This suggests that under certain circumstances, immune tolerance to insulin can be overcome. Factors that can lead to more or less susceptibility to humoral responses to exogenous insulin include the recipient's immune response genes, age, the presence of sufficient circulating autologous insulin, and the site of insulin delivery. Little proof exists, however, that the development of insulin antibodies (IAs) to exogenous insulin therapy affects integrated glucose control, insulin dose requirements, and incidence of hypoglycemia, or contributes to beta-cell failure or to long-term complications of diabetes. Studies in which pregnant women with diabetes were monitored for glycemic control argue against a connection between IAs and fetal risk. Although studies have shown increased levels of immune complexes in patients with diabetic microangiopathic complications, these immune complexes often do not contain insulin or IAs, and insulin administration does not contribute to their formation. The majority of studies have shown no relationship between IAs and diabetic angiopathic complications, including nephropathy, retinopathy, and neuropathy. With the advent of novel insulin formulations and delivery systems, such as insulin pumps and inhaled insulin, examination of these issues is increasingly relevant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
The aging immune system: primer and prospectus
Miller, R. A. (1996) · Science · doi:10.1126/science.273.5271.70 · Cited by 1,165
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668 · cited 1×
“The same was true for the oral insulin treatment arm when all patients were included (366).”
BackgroundHeise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Bolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Kent, S. C., Chen, Y., Bregoli, L., Clemmings, S. M., Kenyon, N. S., Ricordi, C., Hering, B. J., & Hafler, D. A. (2005) · Nature · doi:10.1038/nature03625 · Cited by 409
Diabetes Antibody Standardization Program: first assay proficiency evaluation
Bingley, P. J., Bonifacio, E., Mueller, P. W., & Laboratories, P. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1128 · Cited by 362 · cited 16×
“The age of the individual also affects the presence of IAAs before the development of type 1 diabetes and whether an individual is more or less likely to develop a significant antibody response to exogenous insulin (120).”
MethodInfluentialHyperinsulinemia and Macrosomia in the Fetus of the Diabetic Mother
Schwartz, R., Gruppuso, P. A., Petzold, K., Brambilla, D., Hiilesmaa, V., & Teramo, K. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.640 · Cited by 193
Cited by
De novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531
Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes
Campbell-Thompson, M., Fu, A., Kaddis, J. S., Wasserfall, C., Schatz, D. A., Pugliese, A., & Atkinson, M. A. (2016) · Diabetes · doi:10.2337/db15-0779 · Cited by 356
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Hu, X., & Chen, F. (2018) · Endocrine Connections · doi:10.1530/ec-17-0309 · Cited by 83
Metadata
- Authors
- Fineberg, S. E., Kawabata, T. T., Finco-Kent, D., Fountaine, R. J., Finch, G. L., & Krasner, A. S.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 28
- Issue
- 6
- Pages
- 625-652
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1963524859
- Cited by
- 209
- References
- 12
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.